AmideBio
Boulder, US · Founded 2009 · Colorado LLC
AmideBio uses in-silico design and proprietary peptide synthesis to develop preclinical peptide drug candidates for metabolic disease. It also offers custom peptide synthesis services and a catalog of high-purity peptides for customers.
Founders & leadership
MP
Mikhail PlamExecutive
MH
Michael H.B. StowellNamed on SEC filing
Board
DB
David BarkerBoard director
VP
Vincent P. MihalikBoard director
RC
Ruel C. MercureBoard director
NU
Niles UtlautBoard director
DB
David BrunelBoard director
GA
Gregory AbbottBoard director
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 4 rounds · 2013–2017
▶$763.5KraisedNov 2017 · 9 investors · BiotechnologyRule 506(b)
▶$763.5KraisedNov 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ruel C. MercureDirector
- David BrunelDirector
- Niles UtlautDirector
- Gregory AbbottDirector
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Vincent P. MihalikDirector
- Offering amount
- $763.5K
- Amount sold
- $763.5K
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$396KraisedApr 2017 · 9 investors · BiotechnologyRule 506(b)
▶$396KraisedApr 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Ruel C. MercureDirector
- Gregory AbbottDirector
- Vincent P. MihalikDirector
- David BrunelDirector
- Niles UtlautDirector
- Offering amount
- $768K
- Amount sold
- $396K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$279.3KraisedJan 2015 · 5 investors · BiotechnologyRule 506(b)
▶$279.3KraisedJan 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Vincent P. MihalikDirector
- Michael H.B. StowellExecutive Officer, Director
- Ruel C. MercureDirector
- Mikhail PlamExecutive Officer, Director
- Niles UtlautDirector
- David BrunelDirector
- Gregory AbbottDirector
- Offering amount
- $1.1M
- Amount sold
- $279.3K
- First sale
- Dec 2014
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$400KraisedMay 2014 · 4 investors · BiotechnologyRule 506(b)
▶$400KraisedMay 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mikhail PlamExecutive Officer, Director
- Ruel C. MercureDirector
- Michael H.B. StowellExecutive Officer, Director
- Gregory AbbottDirector
- David BarkerDirector
- Vincent P. MihalikDirector
- Niles UtlautDirector
- Offering amount
- $750K
- Amount sold
- $400K
- First sale
- Dec 2013
- Incorporated
- Limited Liability Company, Colorado, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA7 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Aadi Bioscience7 shared keywordsAadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
Companies competing with AmideBio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $338.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AmideBio do?
- AmideBio uses in-silico design and proprietary peptide synthesis to develop preclinical peptide drug candidates for metabolic disease. It also offers custom peptide synthesis services and a catalog of high-purity peptides for customers.
- How much funding has AmideBio raised?
- AmideBio has disclosed $1.8M raised across 4 rounds.
- Where is AmideBio headquartered?
- AmideBio is headquartered in Boulder, US.